Objectives: Cognitive dysfunction and dementia are common following ischemic stroke. Endothelial nitric oxide synthase (eNOS) has been found to play an important role in neurologic function and cognition. The purpose of the present study was to assess the specific role of eNOS in cognitive performance after stroke. Design: Male wild-type and mice lacking eNOS (eNOS −/− ) underwent middle cerebral artery occlusion or sham-surgery. Primary outcomes were repeated measures of neurologic score, limb asymmetry, sensory/motor function, and spatial memory/learning assessed at intervals up to 28 days postsurgery. Group differences in brain microglia activation and infiltration and levels of interferon-gamma were examined. Results: There was no genotype Â surgery interaction effect on the pattern of change in neurologic score, limb asymmetry, or sensory motor function across the 28 days postsurgery. In the Morris water maze, eNOS −/− middle cerebral artery occlusion mice displayed learning and memory deficits not evident in wild-type middle cerebral artery occlusion mice. Poorer spatial memory and learning in eNOS −/− middle cerebral artery occlusion mice was associated with a reduction in the number of activated microglia in the striatum on the lesion side and decreased brain tissue levels of interferon-gamma. Conclusions: This study's data support a role for eNOS in cognitive performance after stroke. This finding may lead to the development of novel interventions to treat poststroke cognitive deficits.
I
schemic stroke is a leading cause of long-term disability in the adult population. 1 Approximately 30%-50% of stroke survivors are functionally disabled. 2 Poststroke cognitive impairment is a major disabling symptom following stroke and severely affects long-term recovery. The prevalence of cognitive impairment after stroke is about 25%, and the risk of developing a cognitive deficit increases threefold after stroke as compared with nonstroke subjects. 3 The mechanisms underlying poststroke cognitive dysfunction remain unclear, and there are few effective therapies.
Impaired cerebrovascular perfusion is a risk for cognitive dysfunction. 4 The cerebral vasculature produces vasoactive mediators that exert local control of blood vessel diameter and, consequently, tissue perfusion. Nitric oxide (NO) is one of the most important vasoactive factors produced by endothelial cells. Endothelial-derived NO regulates cerebral blood flow by promoting vasodilatation, inhibiting platelet aggregation and leukocyte adherence, and inhibiting vascular smooth muscle cell proliferation. 5 Endothelial NO synthesis is regulated by the enzyme endothelial NO synthase (eNOS), which is widely and constitutively expressed within the endothelial lining of the vascular tree. The generation of mice that lack or partially lack eNOS activity has furthered our understanding of endothelial NO function. Mice lacking eNOS develop hypertension 6 and have an increased propensity to develop stroke. 7 In mouse stroke models, eNOS deficiency results in larger areas of ischemia, worse neurologic outcomes, and larger infarct volumes than in wild-type (WT) mice do. 7 
eNOS
−/− have proven instrumental in defining the role of endothelial function and cerebral blood flow on cognition. Mice lacking or partially lacking eNOS showed age-dependent accumulation of cerebral thrombi and amyloid precursor protein and deficits in spatial memory and learning. [8] [9] [10] In this study, the authors used mice lacking eNOS and the middle cerebral artery occlusion (MCAO) rodent stroke model to test the hypothesis that eNOS deficiency impacts cognitive performance post-stroke.
MATERIALS AND METHODS

Mice and Housing
All the animals were approved by the Institutional Animal Care and Use Committee. Male WT (C57BL/6) and eNOSdeficient (eNOS −/− ; B6.129P2-Nos3tm1Unc/J) mice that were 10-14 wks old and 22-29 g were obtained from Jackson Laboratories (Bar Harbor, ME). Mice were housed in an animal facility (12-hr light/dark cycle) with free access to mouse chow and water. Animals were removed from the study and immediately euthanized based on endpoint criteria including severe infection, seizure, and moribund condition.
Transient MCAO
Mice were anesthetized with a 1% to 2% isofluorane in N 2 O:O 2 (70%:30%) gas mixture via a nose-cone throughout surgery. Body temperature was monitored with a rectal probe and maintained at 37°C ± 0.5°C with a heating pad. Cerebral blood flow was monitored in the region of the middle cerebral artery (MCA) by laser Doppler flowmetry (PeriFlux System 5000; Perimed, Stockholm, Sweden) during surgery. Occlusion of the MCA was achieved by introducing a 6-0 medium surgical filament through the right external carotid artery until the tip occluded the MCA, causing a cessation of blood flow in the MCA territory. After 60 mins, the filament was removed and cerebral blood flow restored. Control mice underwent the same procedure without occlusion of the MCA. Mice received intensive perisurgical care. For analgesia, carprofen (4 mg/kg, subcutaneous) was administrated 30 mins before surgery and every 12 hrs for 72 hrs after surgery. One drop of 0.5% bupivacaine solution was placed on the cut-down sites. Ampicillin (50 mg/kg sc) was administered before surgery and every 12 hrs for 72 hrs after surgery. Mice were provided water gel in the cage until they could freely move to get food and water. Mice were administered normal saline (500 mL, sc) daily for 3 days to prevent dehydration. Mice that developed severe infection, had increased seizure activity, or developed a moribund appearance (i.e., limited mobility, hunched posture, ruffled fur) were immediately killed and removed from the study.
Behavioral Tests
Neurologic score (NS), cylinder test, and the adhesive removal test were conducted on preoperative day 1 and postoperative days 1, 3, 7, 14, 21, and 28. The Morris water maze (MWM) test was conducted on postoperative days 21 to 27. The evaluators of behavioral tests were blinded to the group identification. The behavioral testing schedule is outlined in Suppl. Figure 2 (Supplemental Digital Content 2, http://links. lww.com/PHM/A572).
Neurologic Score
A four-point score test (Bederson scale) was used to assess global neurologic deficits, where 0 = no deficit, 1 = failure to fully extend the forepaw, 2 = circling to one side, and 3 = no spontaneous walking with depressed level of consciousness.
Cylinder Test
Dissymmetry of forelimb movement was assessed using the cylinder test. Mice were placed into a plexiglass cylinder, and the number of times mice used their left, right, or both forepaws to touch the cylinder wall was recorded. Recording stopped after 15 mins or when the total number of contacts reached 20. The lateralization index was calculated as (the number of right paw touches − number of left paw touches)/total number of touches. Data points were excluded if mice made fewer than 10 contacts in 15 mins.
Adhesive Removal Test
The adhesive removal test was used to assess sensorimotor deficits. Adhesive tape was placed on both forepaws with equal pressure. The time to contact the adhesive tape and the time to remove the tape from both paws were recorded.
Spatial Learning and Memory
The MWM test is a widely used test of rodent spatial learning and memory during which mice learn to use distal cues to navigate a direct path to a hidden submerged platform. Briefly, a large circular tank (LE 820120, Panlab, Harvard apparatus) 120 cm in diameter was half filled with water (24°C-26°C). The tank was divided into four equal quadrants (NE, SE, SW, and NW) and a clear Perspex platform 8 cm in diameter was submerged 1.5 cm below the surface of the water in the middle of the NE quadrant. Distal cues were fixed around the tank perimeter and on the testing room walls. Swim performance was recorded by a camera fixed on the ceiling, directly above the center of the pool. Automatic tracking and analysis of each animal's swim path was performed using the WaterMaze Software (Actimetrics, Inc). The experimenter was shielded from the animal during swim training by a curtain and blinded to treatment group. The MWM testing protocol was carried out over a 7-day period on postoperative days 21 to 27. Before each testing day, mice were allowed to acclimate to the testing room in their home cages for at least 30 mins. On day 1, mice were placed gently into the water and allowed to swim for 60 secs, after which they were removed from the tank, dried with a cloth, and returned to their home cage. Learning trials were conducted on days 2 to 6. Mice completed four learning trials each day at 1-hr intervals. For each learning trial, mice were carefully placed into the water facing the side of the tank at one of three different starting points (SE, SW, or NW). The starting location for each learning trial was determined randomly, but all start locations were used in a given day. Mice were allowed to swim to find the submerged platform for 60 secs. The learning trial was terminated and the time taken to find the platform (escape latency) was recorded when the mouse reached the platform and remained on it for 3 secs. If the mouse failed to reach the platform within 60 secs, the trial was terminated, and the mouse was placed on the platform for 15 secs. Reference memory was assessed on day 7, 24 hrs after the final learning trial and with the platform removed. During the probe trial, mice were allowed 60 secs to attempt to find the hidden platform. The total time that mice spent in the quadrant where the platform was previously located was recorded and used as a measure of reference memory. 11, 12 Because sensorimotor deficits can interfere with performance in the MWM by impacting swimming ability and/or motivation to escape from water, swim speed (m/sec) during the learning trial was also recorded using the following equation: total distance traveled/time (seconds).
If a mouse failed to swim but rather floated, the experimenter did not intervene to encourage swimming but rather allowed the mouse to swim for 60 secs before placing on the platform for 15 secs. In addition, mice that were unable to float and were at risk of becoming submerged were immediately removed from the pool and placed upon the platform for 15 secs. A mouse that failed to swim or failed to float after the fourth trial of the day was removed from the experiment and termed a "nonperformer."
Immunohistochemistry Staining
Twenty-eight days after surgery, mice were anesthetized and transcardially perfused with normal saline followed by 4% paraformaldehyde. Whole brain was removed and incubated in 30% sucrose overnight, then frozen at −80°C until sectioning. Before sectioning, brains were embedded in Optimal Cutting Temperature compound (Tissue-Tek, Sakura, Japan). Twenty-micron coronal sections were cut using a cryostat (Leica CM3050). Six sections from the Bregma (0.74 to −1.34 mm with intervals of 400 μm) were selected for immunohistochemistry staining. Sections were incubated in blocking buffer (5% horse serum and 0.4% triton x-100 in 0.01 M phosphate buffered saline [PBS]) at room temperature for 60 mins. To identify microglial cells, brain sections were incubated with anti-Iba-1 primary antibody (rabbit anti-Iba1, 1:200, Abcam) at 4°C for 24 hrs. Anti-Iba-1 antibody binds to ionizing calcium-binding adaptor molecule 1 (Iba-1), a protein that is specifically expressed in microglia and up-regulated when these cells become active. Sections were then washed in 0.01 M PBS for 20 mins before incubation with secondary antibody (Cy3 goat antirabbit immunoglobulin G, 1:500, Life Technologies) for 2 hrs at room temperature in the dark. Finally, sections were washed with 0.01 M PBS before mounting in 4′,6-diamidino-2-phenylindole. Fluorescent images were acquired at 200Â magnification using a Nikon Eclipse TE2000-S fluorescent microscope. The number of Iba1+ cells in the cortex (two fields) and striatum (three fields) in both hemispheres was counted by an observer blinded to the experimental group using the software Image J 1.48u.
Nissl Staining
Nissl staining was performed to delineate the glial scar, which forms in the region of the infarct several days after injury. 13 Brain sections (50 μm) were mounted on targeting molecule polylysine-coated slides and progressively hydrated by incubating in 100% ethanol for 10 mins, 95% ethanol for 2 mins, and distilled water for 2 mins. Sections were then stained with 0.5% cresyl violet for 10 mins and then rinsed rapidly in distilled water. Stained sections were then dehydrated 95% in ethyl alcohol for 3 mins, twice in 100% ethanol for 5 mins, and finally cleared twice in xylene for 5 mins. Finally, sections were covered with neutral resins and a cover slip. The glia scar area was visualized using the software Image J 1.48u.
Brain Tissue Extracts
The brain region between 0 mm and −4 mm posterior to the Bregma was dissected from the contralateral and infarct hemispheres, flash frozen in liquid nitrogen, and then stored at −80°C until protein extraction. Approximately 100 mg of frozen brain tissue was homogenized on ice in 1 mL of tissue extraction reagent (50 mM Tris, 250 mM NaCl, 5 mM ethylenediaminetetraacetic acid, 2 mM Na 3 VO 4 , 1 mM NaF, 20 mM Na 4 P 2 O 7 , 0.02% NaN 3 , and complete protease inhibitors; Roche, Branchburg, NJ). Tissue extracts were centrifuged at 10,000 rpm for 5 mins at 4°C. The supernatant was collected, and the protein concentration was determined using bicinchoninic acid assay. Levels of interferon-gamma (IFN-γ) in brain tissue extracts were measured by enzyme-linked immunosorbent assay (Sigma-Aldrich, Inc, St. Louis, MO) according to the manufacturer's instructions.
Statistical Analysis
All statistical evaluations were performed with SPSS version 23.0 (SPSS Inc, Chicago, IL). Kaplan-Meier survival and logrank tests were used to examine group differences in survival. Chi-square or nonparametric tests were used to examine group differences in performance in the MWM. Two-way analysis of variance (ANOVA) with or without repeated measure was used to determine whether an interaction existed between surgery (MCAO vs. no surgery) and genotype (WT vs. eNOS
) on the functional outcomes tested. Results were expressed as mean ± SD, and statistical significance was accepted at a P value less than 0.05.
RESULTS eNOS Deficiency and MCAO Survival
Twenty-four WT mice and 23 eNOS −/− mice underwent MCAO, and 10 WT and 7 eNOS −/− were sham-treated. There was no significant difference in blood flow during occlusion and reperfusion between WT and eNOS −/− mice in the MCAO group (Suppl. Figure 1 , Supplemental Digital Content 1, http:// links.lww.com/PHM/A571). All mice that underwent the sham procedure survived throughout the 28-day study period. Five of the 24 WT mice and 9 of the 23 eNOS −/− mice met criteria for removal from the study during the 14 days postsurgery (see "METHODS" for detailed criteria for removal). The observed mortality rate in WT MCAO mice is consistent with that reported in the literature.
14 Survival curves shown in Figure 1A revealed no significant difference in survival between WT and eNOS −/− MCAO mice (χ 2 = 1.746, df = 1, P = 0.186). Figure 1B shows body weight change from baseline (day 0) at 14, 21, and 28 days postsurgery in mice that survived the 28-day study period. There was a significant effect of MCAO on weight change over time (F 2.2, 97 = 10.202, P < 0.0001). MCAO mice of both genotypes showed weight loss at 14 days postsurgery, but weight returned to presurgery levels at 21 and 28 days postsurgery. There was no surgery Â genotype interaction effect (F 2.2, 97 = 0.842, P = 0.444).
Neurologic Score
Sham surgery had no effect on NS in WT (n = 10) or eNOS −/− (n = 7) mice (Fig. 1C) . There was a significant effect of MCAO on NS over time (F 9, 414 = 8.652, P < 0.0001). MCAO WT (n = 19) and MCAO eNOS −/− (n = 14) mice displayed mild to moderate deficits (NS score of 1-2) during the first week after surgery, but NS scores improved thereafter. There was no surgery Â genotype interaction effect on NS over time (F 9, 414 = 0.678, P = 0.729).
Adhesive Removal Test Figure 2 shows time to contact (A) and time to remove (B) the tape on the both forepaws. There was an effect of MCAO on contact time (F 1.9, 84 = 3.296, P = 0.043) and removal time (F 3.8, 155.7 = 3.112, P = 0.006). There was no observed impact FIGURE 1. A, Kaplan-Meier survival and log-rank tests were used to determine the group differences in survival. B, The percentage of body weight change from baseline (day 0) at 14, 21, and 28 days post surgery. Shown is the mean ± SEM percentage of weight change in sham and MCAO of WT and eNOS −/− mice that survived the 28-day study period. Means were analyzed by ANOVA with repeated measures. C, General neurologic deficit was assessed using a 4-point (0-3) NS test: 0 = no deficit, 1 = failure to fully extend the forepaw, 2 = circling to one side, 3 = no spontaneous walking with a depressed level of consciousness. The NS was evaluated daily on post-MCAO days 1-10 and then once a week until day 28. Data are expressed as mean ± SEM. Means were analyzed by ANOVA with repeated measures. 
Cylinder Test
Performance in the cylinder test is shown in Figure 3 . There was a significant time Â genotype Â surgery effect on the total number of paw contacts over time (F 3.5, 148 = 4.601, P = 0.0002). Whereas all of the sham-treated mice and 14 of 19 WT MCAO mice were able to make more than 10 paw contacts on post surgery day 1, only 1 of 14 of the eNOS −/− MCAO mice were able to (Fig. 3A) . By day 14 postsurgery, all of the mice, with the exception of two eNOS −/− MCAO mice, contacted the cylinder walls more than 10 times, which allowed calculation of the lateralization index for days 14, 21, and 28 (Fig. 3B) . There was no observed time Â surgery Â genotype interaction effect for lateralization index over time (F 3, 132 = 0.417, P = 0.741).
Spatial Learning and Memory
Performance in the MWM was used as a measure of spatial memory and learning. All of the sham-treated mice (10 WT and 7 eNOS −/− mice) performed in the MWM. One WT MCAO mouse engaged in floating behavior, remaining immobile with its head above water and was labeled a "nonperformer" (see "METHODS" for details). Significantly more eNOS −/− MCAO mice (8/14 mice) failed to perform in the MWM (χ 2 = 9.209, df = 1, P = 0.002, see Table 1 ). Rather than engage in floating behavior, these mice adopted a twisted posture and displayed uncoordinated movement with both the front and hind limbs when placed in the water. Further analyses were conducted only on performer mice that initiated swimming when placed in the MWM. Figure 4A shows escape latency (average time taken to find the submerged platform) and Figure 4B shows swim speed on each of the trial days. For escape latency, a significant effect of surgery was observed on escape latency (P < 0.05) but not genotype for each trial day. There was a genotype Â surgery effect on escape latency on trial days 4 (F 1, 34 = 4.357, P = 0.044) and 5 (F 1, 34 = 8.977, P = 0.005). On these days, mice in the eNOS −/− MCAO group took significantly longer to find the submerged platform than their sham-treated counterparts. In contrast, there was no significant surgery or genotype effect on swim speed for any of the trial days.
In the probe trial conducted on day 7, a significant genotype Â surgery interaction effect was found in time spent in the target quadrant (F 3, 38 = 5.573, P = 0.024). Whereas there was no treatment effect for time in quadrant for WT mice (F 1, 26 = 0.017, P = 0.897) eNOS −/− MCAO mice spent significantly less time in the target quadrant compared with shamtreated eNOS −/− mice (F 1, 11 = 10.961, P = 0.008) (Fig. 4C ).
Difference in Neuroinflammation after MCAO Between WT and eNOS −/− Mice
To evaluate differences in the evolvement of neuroinflammation after MCAO in WT and eNOS −/− MCAO mice, the mice were killed after the conclusion of behavioral testing on day 28 post-MCAO. Nissl staining was used to label the Nissl body in the cytoplasm of neurons and glia and also in neuropils, a dense network composed of glia, dendrites, and unmyelinated axons. Although the infarct area was not readily identifiable, a significantly larger cellular aggregation in the infarcted striatum was observed in WT vs. eNOS −/− mouse brains (Fig. 5A) . Immunostaining brain sections with Iba-I, a pan microglia marker that is up-regulated in activated cells, revealed the specific accumulation of activated microglia in these same brain region (Fig. 5A-D) . Overall, the magnitude of the cell and specifically microglial accumulation was dampened in eNOS −/− MCAO mice (Fig. 5A-D) . Figure MWM was used to examine deficits in spatial learning and memory. Mice were tested on days 21 to 27 after MCAO or sham treatment. A total of 16 WT and 14 eNOS −/− MCAO mice were tested. Three WT MCAO mice were not tested on postoperative day 21 because of technical issues with the water tank that did not allow testing during that time period. A mouse that failed to swim in the MWM was termed a "nonperformer" (See "METHODS" for details).
brain lysates (P < 0.001, Fig. 5E ). Furthermore, the production of IFN-γ substantially increased in WT MCAO (P < 0.001) and eNOS −/− MCAO (P < 0.001) compared with sham WT and sham eNOS −/− , respectively (Fig. 5E ).
DISCUSSION
The present study reveals, for the first time, preliminary evidence of a role for eNOS in cognitive performance poststroke in mice. The findings of this study are consistent with previous work implicating eNOS in cognitive performance in mice without stroke. In a study by Tan et al., 8 young mice with partial eNOS deficiency (eNOS +/− ) developed spontaneous cerebral thromboses, which increased with age, resulting in cognitive deficits that became evident only in mice older than 18 mos of age. In the present study, young WT and eNOS −/− mice (<6 mos old) were used because the authors specifically wanted to examine the impact of eNOS deficiency on stroke outcomes rather than examine the impact of eNOS deficiency and increasing age on stroke-related outcomes. The use of younger mice likely explains why any differences in spatial learning and memory were not detected between sham-treated WT and eNOS −/− mice. Existing clinical studies support a role for eNOS in cognition. For instance, polymorphisms in the eNOS gene are associated with Alzheimer disease. 15 Endothelial dysfunction, specifically loss of endothelial NO, has been shown to be associated with the development of vascular dementia, such as Alzheimer dementia. 8 In addition, synaptic activity during long-term potentiation stimulates NO production, suggesting the role of NO in learning and memory. 16 There is evidence showing that inhibition of NO with nonspecific nitric oxide synthase inhibitors may impair learning and/or memory formation 17, 18 ; however, there are also studies that failed to show any effect on memory. 19, 20 This inconsistency may be related to poor differentiation between the different nitric oxide synthase isoforms.
Based on the Bederson neurologic scoring criteria, a significant difference in neurologic function between WT and eNOS −/− mice after MCAO was not observed. This contrasts to the work of Cui and colleagues, who reported that eNOS −/− mice had significantly reduced neurologic functioning compared to WT mice after MCAO. 21 This inconsistency might be a result of methodologic differences in the length of the occlusion and/or the assessment tools used to document neurologic deficits between the two studies. In the present study, occlusion lasted for 60 mins and the traditional Bederson scale was used to calculate NS. In contrast Cui and colleagues used the Modified Neurological Severity Score. Although the Bederson scoring procedure is easy to perform, it is subjective in nature and because it assesses basic neurologic deficits, it is limited in its ability to detect small deficits in function poststroke. 22 The Modified Neurological Severity Score, however, measures a wider range of sensorimotor deficits including motor, sensory, reflex, and balance and may be more useful in detecting smaller deficits that persist long-term after stroke. 23 The delay in the ability of MCAO eNOS −/− mice to make paw contact with the sides of the cylinder during the 7 days were unable to swim when placed into water maze pool. Failure to swim normally may be additional evidence of prolonged motor or somatosensory deficits in MCAO eNOS −/− mice that were not apparent in the other functional tests used in the present study. Further studies are needed using a larger battery of sensorimotor tests to fully delineate the impact of eNOS deficiency on poststroke functional deficits.
Despite the number of nonperformers, MCAO eNOS −/− that were capable of swimming showed deficits in spatial learning and reference memory during the MWM test. These mice took significantly longer to find the submerged platform on trial days 4 and 5 compared with their WT counterparts. This delay was not related to genotype differences in cognitive performance because there was no significant difference in time to find the platform between WT and eNOS −/− that underwent sham surgery. The speed at which mice swim during the learning trials of the MWM test is commonly used to determine whether or not mice have underlying sensorimotor deficits. There was no difference in swim speed between MCAO eNOS −/− and WT mice across the five training days, which suggests that the delay in finding the platform by MCAO eNOS −/− during the learning trials was not because of ongoing sensorimotor deficits but rather impaired spatial learning.
Mortality rate in MCAO eNOS −/− was approximately twofold greater than in WT mice, although this difference was not statistically significant. The findings of this study are consistent with those of Cui and colleagues, 21 who showed that eNOS −/− had a similar increase in mortality in the 7 days poststroke. Increased mortality may be related to the development of larger infarcts in eNOS −/− . 7 Infarct size was not measured in the present study because the infarct is normally visible only in the days following stroke, where it can be seen as an unstained area of the brain following Nissl staining. At later time points poststroke, the infarct area is less visible and difficult to discern because of the heavier staining of infiltrating reactive astrocytes, microglia, and other cells and the deposition of proteoglycans, which form the glial scar. 13 The darker staining that was observed in the area of the infarct at 28 days post-MCAO likely represents the glial scar rather than the original infarct area. This Nissl stained area was smaller in eNOS . Additional studies are needed to determine whether reduced microglia accumulation in damaged brain tissue of eNOS −/− is a result of reduced microglial proliferation, migration, or both.
It was also demonstrated that levels of IFN-γ were elevated in the infarcted hemisphere compared with the normal hemisphere in WT mice but not in eNOS −/− . Because microglia are able to produce IFN-γ independently of T cells, 24 the reduced IFN-gamma levels in the infarcted hemisphere of eNOS −/− may reflect reduced the accumulation of microglia in the absence of eNOS.
Given the role of microglia in the tissue repair processes poststroke, it is possible that the long-term functional deficits observed in eNOS −/− poststroke are the result of suboptimal angiogenesis and neurogenesis. Brain-derived neurotropic factor (BDNF), a neurotrophin that is abundant in the brain, is upregulated by endothelium NO and plays an important role in poststroke neurogenesis and functional recovery. [25] [26] [27] Although further investigation is warranted, it is intriguing to speculate that the cognitive deficits observed in eNOS −/− in the present study were because of reduced BDNF levels. If this is indeed the case, then therapeutic manipulation of BDNF could offer an effective treatment for poststroke cognitive decline. In a recent study by Harris and colleagues, 28 nanoparticle delivery of BDNF reduced infarct size in mice poststroke and dampened poststroke depressive behavior in the Tail Suspension Test. Although these investigators did not examine cognitive deficits poststroke, a similar strategy could be used to determine whether the eNOSdependent cognitive decline is mediated by BDNF. Additional therapeutic strategies aimed at increasing the production of eNOS have been identified that may prove beneficial at reducing cognitive deficits in stroke survivors in the future. For instance, statins like atorvastatin and simvastatin increase eNOS in experimental animals and may prove beneficial at increasing poststroke function and cognition in the future. 29 
